Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGIuR+ ADHD Adolescents

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that enrollment is complete in the SAGA (Study of Adolescent Glutamate Receptor Network Copy Number Variant ADHD) trial. All ongoing patients are expected to continue through the follow-up period in order to complete the study. The Company anticipates announcing top-line results during the first quarter of 2017.

This entry was posted in Recent Development News: Q1 - 2017, Recent Developments. Bookmark the permalink.
Read Full Article »